Answer
It is unknown whether ivacaftor or its metabolites pass into human breast milk; risk to infants cannot be excluded, so whether to discontinue breastfeeding or discontinue/avoid ivacaftor must be decided by weighing breastfeeding benefits for the child against treatment benefits for the woman.
Sources for this answer
- Kalydeco 150 mg film-coated tabletsVertex Pharmaceuticals (Europe) Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 35Document updated
Sources checked